


RealRate

PHARMACEUTICAL 2020



NGM BIOPHARMACEUTICALS INC Rank 52 of 362





PHARMACEUTICAL 2020





NGM BIOPHARMACEUTICALS INC Rank 52 of 362

The relative strengths and weaknesses of NGM BIOPHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NGM BIOPHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 198% points. The greatest weakness of NGM BIOPHARMACEUTICALS INC is the variable Research and Development, reducing the Economic Capital Ratio by 72% points.

The company's Economic Capital Ratio, given in the ranking table, is 89%, being 392% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	355,248
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	39,718
Liabilities, Non-Current	0
Other Assets	5,680
Other Compr. Net Income	292
Other Expenses	0
Other Liabilities	9,966
Other Net Income	6,545
Property and Equipment	19,475
Research and Development	129,253
Revenues	103,544
Selling, General and Administrative Expense	23,631

Output Variable	Value in 1000 USD
Assets	380,403
Liabilities	49,684
Expenses	152,884
Stockholders Equity	330,719
Net Income	-42,795
Comprehensive Net Income	-42,649
Economic Capital Ratio	89%